117 related articles for article (PubMed ID: 1793726)
1. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex.
Dodion PF; de Valeriola D; Crespeigne N; Kantrowitz JD; Piccart M; Wery F; Kerger J; Egorin MJ; Forrest A; Bachur NR
Ann Oncol; 1991 Sep; 2(8):589-96. PubMed ID: 1793726
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic evaluation of zeniplatin in humans.
DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
[TBL] [Abstract][Full Text] [Related]
3. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity.
Aamdal S; Bruntsch U; Kerger J; Verweij J; ten Bokkel Huinink W; Wanders J; Rastogi R; Franklin HR; Kaye SB
Cancer Chemother Pharmacol; 1997; 40(5):439-43. PubMed ID: 9272122
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
O'Dwyer PJ; Hudes GR; Walczak J; Schilder R; LaCreta F; Rogers B; Cohen I; Kowal C; Whitfield L; Boyd RA
Cancer Res; 1992 Dec; 52(24):6746-53. PubMed ID: 1458462
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of zeniplatin in metastatic melanoma.
Olver I; Green M; Peters W; Zimet A; Toner G; Bishop J; Ketelbey W; Rastogi R; Birkhofer M
Am J Clin Oncol; 1995 Feb; 18(1):56-8. PubMed ID: 7847260
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin.
Olver IN; Webster LK; Millward MJ; Stokes KH; Bishop JF
Cancer Chemother Pharmacol; 1995; 37(1-2):79-85. PubMed ID: 7497601
[TBL] [Abstract][Full Text] [Related]
10. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical evaluation of [SP-4-3(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4- butanediamine-N,N1) platinum in patients with metastatic solid tumors.
Theriault RL; Cohen IA; Esparza L; Kowal C; Raber MN
Cancer Chemother Pharmacol; 1993; 31(4):333-7. PubMed ID: 8422699
[TBL] [Abstract][Full Text] [Related]
12. A Phase I study of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies.
Kim NK; Kim TY; Shin SG; Park YI; Lee JA; Cho YB; Kim KH; Kim DK; Heo DS; Bang YJ
Cancer; 2001 Apr; 91(8):1549-56. PubMed ID: 11301404
[TBL] [Abstract][Full Text] [Related]
13. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.
Willemse PH; Gietema JA; Mulder NH; de Vries EG; Meijer S; Bouma J; Birkhofer M; Rastogi RB; Sleijfer DT
Eur J Cancer; 1993; 29A(3):359-62. PubMed ID: 8398335
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.
Markman M; DeMarco LC; Birkhofer M; Budman D; Hakes T; Reichman B; Rubin S; Jones W; Barakat R; Curtin J
J Cancer Res Clin Oncol; 1993; 119(4):234-6. PubMed ID: 8423199
[TBL] [Abstract][Full Text] [Related]
15. [A phase I study of DWA2114R].
Ariyoshi Y; Wakui A; Hasegawa K; Niitani H; Ogawa M; Sakai Y; Majima H; Furue H; Miyake H; Taguchi T
Gan To Kagaku Ryoho; 1992 May; 19(5):685-93. PubMed ID: 1580642
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
18. [A phase I study on a weekly schedule of DWA2114R].
Niitani H; Fukuoka M; Furusawa M; Tamura M; Hasegawa K; Kurita Y; Ariyoshi Y; Matsunaga T; Kumoi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1027-32. PubMed ID: 1626938
[TBL] [Abstract][Full Text] [Related]
19. A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma.
Kudelka AP; Siddik ZH; Tresukosol D; Edwards CL; Freedman RS; Madden TL; Rastogi R; Hord M; Kim EE; Tornos C; Mante R; Kavanagh JJ
Anticancer Drugs; 1997 Aug; 8(7):649-56. PubMed ID: 9311439
[TBL] [Abstract][Full Text] [Related]
20. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
